ClinicalTrials.gg
CompletedNCT05645276Updated Oct 13, 2026

A Study of AK129 in Patients With Advanced Malignant Tumors

A Phase 1 interventional study of AK129 IV infusion in Advanced Malignant Tumors(Stage IA-IB), sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

Updated Oct 13, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors

Read the detailed description

Anti Lymphocyte Activation Gene-3(LAG-3) combination therapy showed a preliminary antitumor signal in multiple solid tumors and hematologic tumor.LAG-3 targeted drug Relatilimab in a Phase 2/3 study comparing a combination of relatilimab and nivolumab to nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.The combination therapy of Relatilimab with nivolumab showed a statistically significant and clinically significant progression-free survival(PFS) benefit compared to the nivolumab group, Because of this study, the FDA approved the combination therapy for first-line therapy of melanoma.

AK129 is a humanized immunoglobulin G1(IgG1) bispecial antibody(BsAb), which can bind anti-programmed death receptor 1(PD-1) and LAG-3 at the same time, and block the interaction of PD-1/programmed cell death - ligand 1(PD-L1), LAG-3/ major histo-compatibility complex II(MHCII),etc. The aim of the first human, dose-escalation study of this investigational drug is to explore its safety, tolerability, and initial antitumor efficacy, and to evaluate its pharmacokinetic and pharmacokinetic characteristics to identify the appropriate dose and regimen.

02

Conditions studied

  • Advanced Malignant Tumors(Stage IA-IB)
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must sign the written form(ICF) voluntarily.
  2. Aged ≥ 18 to ≤ 75 years.
  3. (ECOG) performance status score of 0 or 1.
  4. ≥ 3 months.
  5. or cytologically confirmed advanced solid tumors(dose-escalation phase) or selected tumor species(pharmacodynamic confirmation phase and dose-expansion phase);Patients with advanced who have failed , or second-line, or third-line, or fourth-line standard therapy, or are ineligible for standard therapy, or cannot tolerate chemotherapy, or are unwilling to receive chemotherapy, or have no effective standard therapy.
  6. Pharmacodynamic confirmation phase and dose expansion phase: at least one measurable tumor lesion( v1.1, lymphoma according to Lugano 2014 evaluation criteria).A lesion from a site previously treated with radiotherapy or other local regional therapy is considered a non-target lesion unless there is definite progression of the lesion or the neoplastic nature of the lesion is confirmed by .
  7. Pharmacodynamic confirmation phase and dose extension phase: All subjects agree to provide archived or freshly obtained tumor tissue samples within 2 years prior to initial administration(formalin-fixed paraffin-embedded (FFPE) tissue wax blocks or approximately 10 unstained tumor tissue sections,and if there is archived tumor tissue within 6 months or 3 months, or freshly obtained tumor tissue, preferably recently obtained tumor tissue samples).
  8. The results of laboratory examination during the screening period indicate that the subjects have good organ function:1).Hematology (no supportive treatment of any component blood and cell growth factors were used within 7 days prior to the start of the study):Neutrophil absolute value(ANC)≥1.5×10\^9/L(solid tumors) or 1.0×10\^9/L(lymphoma); count≥100×10\^9/L(solid tumors) or 75×10\^9/L(lymphoma);≥90 g/L or ≥5.6 mmol/L. 2).Kidney:Serum creatinine(Cr)≤1.5×(ULN),or *(CrCl) calculated value≥ 50 mL/min,CrCl was calculated by Cockcroft-Gault formula:CrCl (mL/min)={(140-age)×weight(kg)×F}/(SCr (mg/dL)×72),Male F=1,Female F=0.85,SCr=serum creatinine.3).Liver:Serum total (TBil)≤1.5×ULN,Subjects with confirmed/suspected Gilbert disease,TBil ≤ 3× ULN;(AST) and alanine aminotransferase(ALT) ≤ 2.5×ULN,For subjects with liver metastasis or liver cancer,AST and ALT ≤ 5×ULN.4).Blood clotting function:Internationally standardized ratio()≤ 1.5×ULN and activated partial thromboplastin time(APTT)≤ 1.5×ULN(If the subject is receiving anticoagulant therapy, the subject will receive a steady dose of anticoagulant and the coagulation parameters(prothrombin time(PT)/INR and APTT) will be within the expected range of anticoagulant therapy at the time of screening).5).Cardiac function:(LVEF)≥ 50%;Troponin protein T or I\<2×ULN.
  9. Fertile female subjects must undergo a negative serum pregnancy test within 3 days prior to initial medication.If a fertile female subject has sex with an unsterilized male partner, the subject must initiate a highly effective method from screening and must agree to continue using these precautions until 120 days after the final administration of the study drug;Periodic abstinence, safe period contraception and extracorporeal ejaculation are not acceptable contraceptive methods;
  10. If an unsterilized male subject has sex with a fertile female partner, the subject must use an effective contraceptive method from the beginning of screening to within 120 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Active central nervous system .
  2. Subjects with uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring repeated drainage(frequency greater than monthly).
  3. Patients with other active malignant tumors within 2 years prior to the first administration, except for locally curable tumor species and those who have been cured, such as squamous cell carcinoma of the skin, basal cell carcinoma of the skin, superficial bladder carcinoma, and carcinoma in situ of the breast.
  4. Known primary or secondary immunodeficiency,including (HIV) antibodies tested positive.
  5. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  6. Known interstitial lung disease or non-infectious pneumonia requiring therapy;Except for those caused by radiation therapy.
  7. Severe infections, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia, occur within 4 weeks prior to initial administration.
  8. Present with active infections(including active tuberculosis and active treponema pallidum) requiring systemic treatment, and have used systemic antibacterial, antiviral or antifungal drugs within 2 weeks prior to initial administration;Note: Antiviral drugs for viral are excluded.
  9. Subjects with active viral hepatitis B, non-active or asymptomatic hepatitis B virus(HBV) carriers(Hepatitis B surface antigen(HBsAg) positive) with HBV deoxyribonucleic acid(DNA)>200IU/mL, and subjects with active viral .
  10. Have active or documented inflammatory bowel disease(e.g. Crohn's disease, ulcerative colitis), active diverticulitis.
  11. Any of the following cardiovascular and cerebrovascular diseases:a.Myocardial infarction, unstable angina pectoris, pulmonary embolism, aortic dissection, deep vein thrombosis, and any arterial thromboembolism events occurred within 6 months prior to initial administration;b.(NYHA) cardiac functional grade ≥ II for heart failure;c. Severe arrhythmias requiring long-term drug intervention; Subjects with asymptomatic and stable ventricular frequency of atrial fibrillation were admitted.d.Uncontrolled hypertension(defined as systolic blood pressure>150 mmHg and diastolic blood pressure>100 mmHg) with sufficient antihypertensive medication, or a history of hypertensive crisis or hypertensive encephalopathy.
  12. Received the following antitumor drugs or treatments before initial administration:a. Received monoclonal antibody drugs(including /L1) immunotherapy drugs within 6 weeks prior to initial administration or within 5 half-time period of the drug, whichever is shorter;b. Received small-molecule targeted drugs, immunomodulatory drugs , Chinese generic drugs with anti-tumor indications, or palliative radiotherapy within 2 weeks prior to initial administration;c. Received other types of antitumor therapy, including chemotherapy, radical radiotherapy, or any unapproved drug within 4 weeks prior to initial dosing;d. Major surgical treatment within 4 weeks prior to initial administration.
  13. Dose expansion phase: Immunocheckpoint inhibitors targeting LAG-3 were previously used.
  14. Subjects requiring therapy with glucocorticoids(prednisone>10 mg/ day or equivalent of glucocorticoids) or other agents within 14 days prior to initial administration;The following are excluded:a. Glucocorticoids as prophylactic drugs for reactions(such as medication before Computed Tomography(CT) examination).
  15. was administered within 4 weeks prior to initial administration.
  16. No remission of toxicity from previous antitumor therapy was defined as failure to return to National Cancer Institute (NCI CTCAE) v5.0≤1 or the level specified in the inclusion/exclusion criteria(except hair loss).
  17. A known history of severe hypersensitivity to other monoclonal antibodies.
  18. Any condition that the investigator believes may result in a risk of receiving the study drug or interfere with the evaluation of the study drug or the subject's safety or the interpretation of the study results.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    The dose escalation stage, pharmacodynamic confirmation stage and dose expansion stage of AK129

    7 dose groups were set up, which were 0.03mg/kg,0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg and 25 mg/kg in dose escalation stage; 2-3 dose levels that do not exceed maximum tolerated dose(MTD) may be selected for pharmacodynamic confirmation cohort extension in pharmacodynamic confirmation stage;Five cohorts with different indications were included in each group with 10-20 subjects in dose expansion stage.

    Drug: AK129 IV infusion

Interventions

  • AK129 is administered intravenously according to the frequency and dosage of administration at different stages.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events(AE)

    Incidence and severity of AEs is aim to evaluate the safety of AK129

    Time frame: Up to approximately 2 years

  2. Incidence of serious adverse events(SAE)

    Incidence of SAE is aim to evaluate the safety of AK129

    Time frame: Up to approximately 2 years

  3. The incidence of suspected unexpected serious adverse reactions(SUSAR)

    The incidence of SUSAR is aim to evaluate the safety of AK129

    Time frame: Up to approximately 2 years

  4. Incidence of dose-limiting toxicity(DLT)

    The purpose of DLT is to find the Phase II recommended dose(RP2D) or MTD

    Time frame: Up to approximately 2 years

  5. Number of participants with clinically significant changes in laboratory assessment data as assessed by CTCAE v5.0.

    Monitor and summerize all data derive from clinically significant changes in laboratory assessment data per Common Terminology Criteria for Adverse Events(CTCAE)5.0.

    Time frame: Up to approximately 2 years

  6. AE that leads to the termination or suspension of treatment

    AE that leads to the termination or suspension of treatment is aim to evaluate the safety of AK129

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective response rate(ORR)

    ORR is proportion of subjects with complete response(CR) or partial response(PR), based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(Solid Tumor)or Lugano 2014 Evaluation Criteria(lymphoma)

    Time frame: Up to approximately 2 years

  2. Disease control rate(DCR)

    Disease control rate(DCR) is defined as the proportion of subjects achieving a best of response(BOR) of confirmed CR and PR and stable disease(SD) per RECIST v1.1(Solid Tumor)or Lugano 2014 Evaluation Criteria(lymphoma)

    Time frame: Up to approximately 2 years

  3. duration of response(DoR)

    Duration of response(DoR) is defined as the period from the first documentation of confirmed response(CR or PR) to the first documentation of progressive disease(PD) (as per RECIST v1.1(Solid Tumor)or Lugano 2014 Evaluation Criteria(lymphoma)) or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  4. time to response(TTR)

    Time to response(TTR) is defined as the time from the first dose of investigational products until the first confirmation of CR or PR

    Time frame: Up to approximately 2 years

  5. progression-free survival(PFS)

    Progression-free survival(PFS) is defined as the time from the first dose of investigational products until documentation of PD(progressive disease)(as per RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  6. overall survival(OS)

    Overall survival(OS) is defined as the time from the first dose of investigational products until death due to any cause.

    Time frame: Up to approximately 2 years

  7. The drug concentration of AK129 in serum

    The drug concentration of AK129 in serum was used to assess the blood concentration of AK129 at different dosing time points.

    Time frame: Up to approximately 2 years

  8. maximum concentration(Cmax)

    Maximum concentration(Cmax) is to evaluate the Pharmacokinetics(PK) of AK129.

    Time frame: Up to approximately 2 years

  9. peak time(Tmax)

    Peak time(Tmax)is to evaluate the Pharmacokinetics(PK) of AK129.

    Time frame: Up to approximately 2 years

  10. half time(t1/2)

    Half time(t1/2) is to evaluate the Pharmacokinetics(PK) of AK129.

    Time frame: Up to approximately 2 years

  11. area under curve(AUC)

    Area under curve(AUC) is to evaluate the Pharmacokinetics(PK) of AK129.

    Time frame: Up to approximately 2 years

  12. clearance rate(CL)

    Clearance rate(CL) is to evaluate the Pharmacokinetics(PK) of AK129.

    Time frame: Up to approximately 2 years

  13. apparent volume of distribution(Vd)

    Apparent volume of distribution(Vd) is to evaluate the Pharmacokinetics(PK) of AK129.

    Time frame: Up to approximately 2 years

  14. Number and percentage of subjects with anti-drug antibody(ADA) to AK129

    The immunogenicity of AK129 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).

    Time frame: Up to approximately 2 years

07

Study locations

1 site
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing Municipality 100021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Jun 2026, 39 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jun 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2022
First posted
Dec 9, 2022
StartActual
Mar 3, 2023
Primary completionActual
Jun 9, 2026was Feb 2026
CompletionActual
Jun 9, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Cancer Hospital Chinese Academy of Medical Science · Beijing, China
Show 1 removed
  • Cancer Hospital Chinese Academy of Medical Science · Beijing, China
Oct 13, 2026
Start date
Mar 2, 2023→Mar 3, 2023
Oct 13, 2026
Primary completion
Feb 2026→Jun 9, 2026 (actual)
Oct 13, 2026
Enrollment
182 (estimated)→57 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Cancer Hospital Chinese Academy of Medical Science · Beijing, China
    Show 1 removed
    • Cancer Hospital Chinese Academy of Medical Science · Beijing, China
    Start date Mar 2, 2023→Mar 3, 2023
    Primary completion Feb 2026→Jun 9, 2026 (now actual)
    Enrollment 182 (estimated)→57 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05645276
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Mar 3, 2023
Primary completion
Jun 9, 2026
Completion
Jun 9, 2026
Last update
Oct 13, 2026

Study contacts

Jie Wang, Doctor
principal investigator · Cancer Hospital Chinese Academy of Medical Science

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/LAG-3 Bispecific Antibody AK129

Start the discussion